The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline testing for men with prostate cancer: Need to broaden the indications in Europe?
 
Elena Trevisi
No Relationships to Disclose
 
Kira-Lee Koster
No Relationships to Disclose
 
Karl Heinimann
No Relationships to Disclose
 
Ursina Zuerrer
No Relationships to Disclose
 
Fabio Turco
No Relationships to Disclose
 
Davide Giovanni Bosetti
No Relationships to Disclose
 
Ilaria Colombo
Employment - Medacta (I); Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I)
Honoraria - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Consulting or Advisory Role - MSD Oncology
Research Funding - Bayer (Inst); MSD (Inst); Oasmia Pharmaceutical AB (Inst)
Travel, Accommodations, Expenses - Tesaro
 
Silvia Maitz
No Relationships to Disclose
 
Marta Nerone
No Relationships to Disclose
 
Aurelius Gabriel Omlin
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Speakers' Bureau - Advanced accelerator; Astellas Pharma; Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag; Janssen-Cilag (Inst)
Research Funding - Janssen (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi
 
Ursula Vogl
Honoraria - SAMO, OegHO, Healthbook, Inselspital Berna, Kantonsspital Arau, Kontonsspital Chur (Inst)
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Merck (Inst)
Travel, Accommodations, Expenses - Janssen; Merck
 
Silke Gillessen
Consulting or Advisory Role - AAA HealthCare (Inst); Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer (Inst); BMS (Inst); ESMO; German-speaking European School of Oncology (DESO); Modra Pharmaceuticals (Inst); MSD Oncology; MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Radiotelevisione Svizzera Italiana (RSI); Silvio Grasso Consulting (Inst); Swiss Academy of Multidisciplinary oncology (SAMO); Swiss Group for Clinical Cancer Research (SAKK); Telix Pharmaceuticals (Inst); TOLREMO (Inst); WebMD/Medscape (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - ProteoMediX
 
Rossella Graffeo
No Relationships to Disclose